1,*Chemical and Biochemical lab, A1 Global Institute of Engineering and Technology, Markapur-523316, Andhra Pradesh, India.
2,*Department of Chemistry, AMET University, Kanathur, Chennai-603112, Tamilnadu, India.
3Department of Zoology, St. Mary's College (Autonomous), Thoothukudi - 626001, Tamilnadu, India.
4Bioprospecting Research Unit, Saveetha Medical College and Hospital, Saveetha Institute of Medical and Technical Sciences (SIMATS), Thandalam, Chennai-602105, Tamil Nadu, India.
The present study was aimed to adopt different strategy to enhance the production of pravastatin by Mucor hiemalis MTCC-157 using resting cells. Response surface methodology (RSM) was applied for optimization of process variables. The optimum values for maximum bioconversion of mevastatin to pravastatin was obtained using substrate concentration (mevastatin)-158.28 (mg 100mL⁻¹), Biotransformation time-25.08(h), Cell concentration-5.98 (g 100 mL⁻¹), Age of inoculum-55.44(h) and pH-5.29. The pravastatin production of 1310.01 mg L⁻¹ was obtained. Response surface methodology (RSM) was employed to evaluate the optimal combination of each parameter for maximum bioconversion. In this work also relates to fed batch resting cells of M. hiemalis produce maximum pravastatin. Simple media such as carbon (glycerol) and mevastatin was used. Further, there is no nitrogen sources, and no other micronutrients were used to produce pravastatin. So that pravastatin can easily be isolated from fermentation broth. The novelty of this method of pravastatin production is no much purification steps are required for separation. This is, to our best knowledge, the first study detailing on bioconversion of mevastatin to pravastatin production using resting cells in SmF.
Keywords: Bioconversion, mevastatin, pravastatin, optimization, response surface methodology.
How to cite this article: Syed MB, Santharaman P, Niranjani R, Veerabadhran M, Dorothy S, Dhinesh Kumar M, Maheshwaran A, Manikandan C. Bioconversion of mevastatin to pravastatin using resting cells of Mucor hiemalis. Int J Drug Deliv Technol. 2026;16(15s): 1067-1074. DOI: 10.25258/ijddt.16.15s.118
Source of support: Nil.
Conflict of interest: None